ORGANIZATION

Japan No. 3 Originator Country in Global Top 100 Drug List in 2020: JPMA Think Tank

November 11, 2021
Japan ranked third in terms of the countries of origin of the world’s 100 top-selling drugs in 2020 after the US and Switzerland, according to research by a think tank arm of the Japan Pharmaceutical Manufacturers Association. The US topped…

To read the full story

ORGANIZATION

By Yoshinori Sagehashi

“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…

By Philip Carrigan

Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…

Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…